Bifidobacterium longum R0175 Protects Rats against D-Galactosamine-Induced Acute Liver Failure

被引：31

作者：

Wang, Kaicen ^{[1
,2
,3
]}

Lv, Longxian ^{[1
,2
,3
]}

Yan, Ren ^{[1
,2
,3
]}

Wang, Qiangqiang ^{[1
,2
,3
]}

Jiang, Huiyong ^{[1
,2
,3
]}

Wu, Wenrui ^{[1
,2
,3
]}

Li, Yating ^{[1
,2
,3
]}

Ye, Jianzhong ^{[1
,2
,3
,4
]}

Wu, Jingjing ^{[1
,2
,3
]}

Yang, Liya ^{[1
,2
,3
]}

Bian, Xiaoyuan ^{[1
,2
,3
]}

Jiang, Xianwan ^{[1
,2
,3
]}

Lu, Yanmeng ^{[1
,2
,3
]}

Xie, Jiaojiao ^{[1
,2
,3
]}

Wang, Qing ^{[1
,2
,3
]}

Shen, Jian ^{[1
,2
,3
]}

Li, Lanjuan ^{[1
,2
,3
]}

机构：

[1] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China

[2] Zhejiang Univ, Natl Clin Res Ctr Infect Dis, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China

[3] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China

[4] Wenzhou Med Coll, Dept Lab, Affiliated Hosp 1, Wenzhou, Peoples R China

来源：

MSPHERE | 2020年 / 5卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Bifidobacterium longum R0175; acute liver failure; metabolome; microbiome; probiotic; BUTYRICIMONAS-VIROSA BACTEREMIA; LACTOBACILLUS-HELVETICUS R0052; IMMUNE-RESPONSE; GUT FLORA; FORMULATION; METHIONINE; HEALTH; METABOLISM; MICROBIOTA; CELLS;

D O I：

10.1128/mSphere.00791-19

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on Bifidobacterium longum R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of B. longum R0175 against acute liver failure caused by D-galactosamine (D-GalN) in rats and further tested the hypothesis that B. longum R0175 exerted liver-protective effects by affecting the intestinal microbiota and fecal metabolites and by inhibiting inflammation. We found that oral gavage of B. longum R0175 markedly reduced the severity of liver injury in D-GalN-treated rats, as evidenced by decreased serum levels of aspartate aminotransferase (AST) and total bile acids (TBAs) (P < 0.05). Moreover, the plasma concentrations of proinflammatory cytokines (interleukin 1 beta [IL-1 beta] and tumor necrosis factor-alpha [TNF-alpha]) and chemokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage chemoattractant protein 1 [MCP-1], chemokine [C-X-C motif] ligand 1 [CXCL1], chemokine [C-C motif] ligand 5 [CCL5], and macrophage inflammatory protein-1 alpha [MIP-1 alpha]) were also markedly reduced (P < 0.05). Pretreatment with B. longum R0175 partially reversed the gut microbiota dysbiosis in rats with liver injury by increasing the relative abundances of potentially beneficial bacteria, such as Alloprevotella spp., and decreasing the relative abundances of potentially harmful bacteria, such as Acetatifactor muris, Butyricimonas spp., and Oscillibacter spp. Furthermore, B. longum R0175 administration partially improved the metabolic function of the intestinal microbes, as indicated by the decreased level of lithocholic acid found in the feces. IMPORTANCE Our research investigated the protective and preventive roles of B. longum R0175 in a rat model of acute liver failure. The results illustrated that this probiotic strain exhibited protective effects in rats with acute liver failure. Thus, B. longum R0175 showed clinical application prospects that required further exploration.

引用

页数：14